Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial.

Elizaga ML, Li SS, Kochar NK, Wilson GJ, Allen MA, Tieu HVN, Frank I, Sobieszczyk ME, Cohen KW, Sanchez B, Latham TE, Clarke DK, Egan MA, Eldridge JH, Hannaman D, Xu R, Ota-Setlik A, McElrath MJ, Hay CM; NIAID HIV Vaccine Trials Network (HVTN) 087 Study Team.

PLoS One. 2018 Sep 20;13(9):e0202753. doi: 10.1371/journal.pone.0202753. eCollection 2018.

2.

Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine.

Cheeseman HM, Day S, McFarlane LR, Fleck S, Miller A, Cole T, Sousa-Santos N, Cope A, Cizmeci D, Tolazzi M, Hwekwete E, Hannaman D, Kratochvil S, McKay PF, Chung AW, Kent SJ, Cook A, Scarlatti G, Abraham S, Combadiere B, McCormack S, Lewis DJ, Shattock RJ.

Hum Gene Ther. 2018 Sep;29(9):1011-1028. doi: 10.1089/hum.2018.075.

4.

Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial.

Patel PM, Ottensmeier CH, Mulatero C, Lorigan P, Plummer R, Pandha H, Elsheikh S, Hadjimichael E, Villasanti N, Adams SE, Cunnell M, Metheringham RL, Brentville VA, Machado L, Daniels I, Gijon M, Hannaman D, Durrant LG.

Oncoimmunology. 2018 Feb 22;7(6):e1433516. doi: 10.1080/2162402X.2018.1433516. eCollection 2018.

5.

Comparative functional potency of DNA vaccines encoding Plasmodium falciparum transmission blocking target antigens Pfs48/45 and Pfs25 administered alone or in combination by in vivo electroporation in rhesus macaques.

Datta D, Bansal GP, Grasperge B, Martin DS, Philipp M, Gerloff D, Ellefsen B, Hannaman D, Kumar N.

Vaccine. 2017 Dec 15;35(50):7049-7056. doi: 10.1016/j.vaccine.2017.10.042. Epub 2017 Nov 10.

PMID:
29132995
6.

Combined skin and muscle vaccination differentially impact the quality of effector T cell functions: the CUTHIVAC-001 randomized trial.

Haidari G, Cope A, Miller A, Venables S, Yan C, Ridgers H, Reijonen K, Hannaman D, Spentzou A, Hayes P, Bouliotis G, Vogt A, Joseph S, Combadiere B, McCormack S, Shattock RJ.

Sci Rep. 2017 Oct 12;7(1):13011. doi: 10.1038/s41598-017-13331-1.

7.

DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA.

Li SS, Kochar NK, Elizaga M, Hay CM, Wilson GJ, Cohen KW, De Rosa SC, Xu R, Ota-Setlik A, Morris D, Finak G, Allen M, Tieu HV, Frank I, Sobieszczyk ME, Hannaman D, Gottardo R, Gilbert PB, Tomaras GD, Corey L, Clarke DK, Egan MA, Eldridge JH, McElrath MJ, Frahm N; NIAID HIV Vaccine Trials Network.

Clin Vaccine Immunol. 2017 Nov 6;24(11). pii: e00263-17. doi: 10.1128/CVI.00263-17. Print 2017 Nov.

8.

A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models.

Garrison AR, Shoemaker CJ, Golden JW, Fitzpatrick CJ, Suschak JJ, Richards MJ, Badger CV, Six CM, Martin JD, Hannaman D, Zivcec M, Bergeron E, Koehler JW, Schmaljohn CS.

PLoS Negl Trop Dis. 2017 Sep 18;11(9):e0005908. doi: 10.1371/journal.pntd.0005908. eCollection 2017 Sep.

9.

An immunoinformatics-derived DNA vaccine encoding human class II T cell epitopes of Ebola virus, Sudan virus, and Venezuelan equine encephalitis virus is immunogenic in HLA transgenic mice.

Bounds CE, Terry FE, Moise L, Hannaman D, Martin WD, De Groot AS, Suschak JJ, Dupuy LC, Schmaljohn CS.

Hum Vaccin Immunother. 2017 Dec 2;13(12):2824-2836. doi: 10.1080/21645515.2017.1329788. Epub 2017 Jun 2.

10.

Immunogenicity and malaria transmission reducing potency of Pfs48/45 and Pfs25 encoded by DNA vaccines administered by intramuscular electroporation.

Datta D, Bansal GP, Gerloff DL, Ellefsen B, Hannaman D, Kumar N.

Vaccine. 2017 Jan 5;35(2):264-272. doi: 10.1016/j.vaccine.2016.11.072. Epub 2016 Nov 29.

11.

A phase 1, randomized, controlled dose-escalation study of EP-1300 polyepitope DNA vaccine against Plasmodium falciparum malaria administered via electroporation.

Spearman P, Mulligan M, Anderson EJ, Shane AL, Stephens K, Gibson T, Hartwell B, Hannaman D, Watson NL, Singh K.

Vaccine. 2016 Nov 4;34(46):5571-5578. doi: 10.1016/j.vaccine.2016.09.041. Epub 2016 Sep 30.

12.

Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adults.

Mutua G, Farah B, Langat R, Indangasi J, Ogola S, Onsembe B, Kopycinski JT, Hayes P, Borthwick NJ, Ashraf A, Dally L, Barin B, Tillander A, Gilmour J, De Bont J, Crook A, Hannaman D, Cox JH, Anzala O, Fast PE, Reilly M, Chinyenze K, Jaoko W, Hanke T, Hiv-Core 004 Study Group T.

Mol Ther Methods Clin Dev. 2016 Aug 31;3:16061. doi: 10.1038/mtm.2016.61. eCollection 2016.

13.

A Phase 1 clinical trial of a DNA vaccine for Venezuelan equine encephalitis delivered by intramuscular or intradermal electroporation.

Hannaman D, Dupuy LC, Ellefsen B, Schmaljohn CS.

Vaccine. 2016 Jun 30;34(31):3607-12. doi: 10.1016/j.vaccine.2016.04.077. Epub 2016 May 17.

PMID:
27206386
14.

The improved antibody response against HIV-1 after a vaccination based on intrastructural help is complemented by functional CD8+ T cell responses.

Storcksdieck genannt Bonsmann M, Niezold T, Hannaman D, Überla K, Tenbusch M.

Vaccine. 2016 Apr 4;34(15):1744-51. doi: 10.1016/j.vaccine.2016.02.059. Epub 2016 Mar 3.

PMID:
26945099
15.

Enhancing the Quality of Antibodies to HIV-1 Envelope by GagPol-Specific Th Cells.

Storcksdieck genannt Bonsmann M, Niezold T, Temchura V, Pissani F, Ehrhardt K, Brown EP, Osei-Owusu NY, Hannaman D, Hengel H, Ackerman ME, Streeck H, Nabi G, Tenbusch M, Überla K.

J Immunol. 2015 Nov 15;195(10):4861-72. doi: 10.4049/jimmunol.1501377. Epub 2015 Oct 14.

16.

Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses.

Bounds CE, Kwilas SA, Kuehne AI, Brannan JM, Bakken RR, Dye JM, Hooper JW, Dupuy LC, Ellefsen B, Hannaman D, Wu H, Jiao JA, Sullivan EJ, Schmaljohn CS.

PLoS One. 2015 Sep 30;10(9):e0137786. doi: 10.1371/journal.pone.0137786. eCollection 2015.

17.

A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.

Mpendo J, Mutua G, Nyombayire J, Ingabire R, Nanvubya A, Anzala O, Karita E, Hayes P, Kopycinski J, Dally L, Hannaman D, Egan MA, Eldridge JH, Syvertsen K, Lehrman J, Rasmussen B, Gilmour J, Cox JH, Fast PE, Schmidt C.

PLoS One. 2015 Aug 7;10(8):e0134287. doi: 10.1371/journal.pone.0134287. eCollection 2015.

18.

Evaluation of the Impact of Codon Optimization and N-Linked Glycosylation on Functional Immunogenicity of Pfs25 DNA Vaccines Delivered by In Vivo Electroporation in Preclinical Studies in Mice.

Datta D, Bansal GP, Kumar R, Ellefsen B, Hannaman D, Kumar N.

Clin Vaccine Immunol. 2015 Sep;22(9):1013-9. doi: 10.1128/CVI.00185-15. Epub 2015 Jul 1.

19.

Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges.

Grant-Klein RJ, Altamura LA, Badger CV, Bounds CE, Van Deusen NM, Kwilas SA, Vu HA, Warfield KL, Hooper JW, Hannaman D, Dupuy LC, Schmaljohn CS.

Hum Vaccin Immunother. 2015;11(8):1991-2004. doi: 10.1080/21645515.2015.1039757.

20.

DNA vaccines encoding DEC205-targeted antigens: immunity or tolerance?

Niezold T, Storcksdieck Genannt Bonsmann M, Maaske A, Temchura V, Heinecke V, Hannaman D, Buer J, Ehrhardt C, Hansen W, Überla K, Tenbusch M.

Immunology. 2015 Aug;145(4):519-33. doi: 10.1111/imm.12467. Epub 2015 Apr 30.

21.

Effects of APC De-targeting and GAr modification on the duration of luciferase expression from plasmid DNA delivered to skeletal muscle.

Subang MC, Fatah R, Wu Y, Hannaman D, Rice J, Evans CF, Chernajovsky Y, Gould D.

Curr Gene Ther. 2015;15(1):3-14.

22.

Optimization of the immunogenicity of a DNA vaccine encoding a bacterial outer membrane lipoprotein.

Buaklin A, Palaga T, Hannaman D, Kerdkaew R, Patarakul K, Jacquet A.

Mol Biotechnol. 2014 Oct;56(10):903-10. doi: 10.1007/s12033-014-9769-6.

PMID:
24870617
23.

Control of HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the absence of CD4+ T cells.

Peng S, Song L, Knoff J, Wang JW, Chang YN, Hannaman D, Wu TC, Alvarez RD, Roden RB, Hung CF.

Cell Biosci. 2014 Mar 4;4(1):11. doi: 10.1186/2045-3701-4-11.

24.

DNA electroporation of multi-agent vaccines conferring protection against select agent challenge: TriGrid delivery system.

Keane-Myers AM, Bell M, Hannaman D, Albrecht M.

Methods Mol Biol. 2014;1121:325-36. doi: 10.1007/978-1-4614-9632-8_29.

PMID:
24510836
25.

Novel vaccine regimen elicits strong airway immune responses and control of respiratory syncytial virus in nonhuman primates.

Grunwald T, Tenbusch M, Schulte R, Raue K, Wolf H, Hannaman D, de Swart RL, Uberla K, Stahl-Hennig C.

J Virol. 2014 Apr;88(8):3997-4007. doi: 10.1128/JVI.02736-13. Epub 2014 Jan 22.

26.

A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for haemorrhagic fever with renal syndrome delivered by intramuscular electroporation.

Hooper JW, Moon JE, Paolino KM, Newcomer R, McLain DE, Josleyn M, Hannaman D, Schmaljohn C.

Clin Microbiol Infect. 2014 May;20 Suppl 5:110-7. doi: 10.1111/1469-0691.12553. Epub 2014 Mar 7.

27.

Protective efficacy and immunogenicity of a combinatory DNA vaccine against Influenza A Virus and the Respiratory Syncytial Virus.

Stab V, Nitsche S, Niezold T, Storcksdieck Genannt Bonsmann M, Wiechers A, Tippler B, Hannaman D, Ehrhardt C, Uberla K, Grunwald T, Tenbusch M.

PLoS One. 2013 Aug 14;8(8):e72217. doi: 10.1371/journal.pone.0072217. eCollection 2013.

28.

Epitope-based DNA vaccine for Alzheimer's disease: translational study in macaques.

Evans CF, Davtyan H, Petrushina I, Hovakimyan A, Davtyan A, Hannaman D, Cribbs DH, Agadjanyan MG, Ghochikyan A.

Alzheimers Dement. 2014 May;10(3):284-95. doi: 10.1016/j.jalz.2013.04.505. Epub 2013 Jul 31.

29.

Functional evaluation of malaria Pfs25 DNA vaccine by in vivo electroporation in olive baboons.

Kumar R, Nyakundi R, Kariuki T, Ozwara H, Nyamongo O, Mlambo G, Ellefsen B, Hannaman D, Kumar N.

Vaccine. 2013 Jun 28;31(31):3140-7. doi: 10.1016/j.vaccine.2013.05.006. Epub 2013 May 16.

30.

HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques.

Li J, Valentin A, Kulkarni V, Rosati M, Beach RK, Alicea C, Hannaman D, Reed SG, Felber BK, Pavlakis GN.

Vaccine. 2013 Aug 12;31(36):3747-55. doi: 10.1016/j.vaccine.2013.04.037. Epub 2013 Apr 26.

31.

Optimization of a Der p 2-based prophylactic DNA vaccine against house dust mite allergy.

Pulsawat P, Pitakpolrat P, Prompetchara E, Kaewamatawong T, Techakriengkrai N, Sirivichayakul S, Buranapraditkun S, Hannaman D, Ruxrungtham K, Jacquet A.

Immunol Lett. 2013 Mar;151(1-2):23-30. doi: 10.1016/j.imlet.2013.01.013. Epub 2013 Feb 8.

PMID:
23396105
32.

A single electroporation delivery of a DNA vaccine containing the hemagglutinin gene of Asian H5N1 avian influenza virus generated a protective antibody response in chickens against a North American virus strain.

Ogunremi O, Pasick J, Kobinger GP, Hannaman D, Berhane Y, Clavijo A, van Drunen Littel-van den Hurk S.

Clin Vaccine Immunol. 2013 Apr;20(4):491-500. doi: 10.1128/CVI.00577-12. Epub 2013 Jan 30.

33.

Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma.

Yuan J, Ku GY, Adamow M, Mu Z, Tandon S, Hannaman D, Chapman P, Schwartz G, Carvajal R, Panageas KS, Houghton AN, Wolchok JD.

J Immunother Cancer. 2013 Nov 18;1:20. doi: 10.1186/2051-1426-1-20. eCollection 2013.

34.

Two doses of bovine viral diarrhea virus DNA vaccine delivered by electroporation induce long-term protective immune responses.

van Drunen Littel-van den Hurk S, Lawman Z, Snider M, Wilson D, van den Hurk JV, Ellefsen B, Hannaman D.

Clin Vaccine Immunol. 2013 Feb;20(2):166-73. doi: 10.1128/CVI.00565-12. Epub 2012 Dec 5.

35.

Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine.

Peng S, Lyford-Pike S, Akpeng B, Wu A, Hung CF, Hannaman D, Saunders JR, Wu TC, Pai SI.

Cancer Immunol Immunother. 2013 Jan;62(1):171-82. doi: 10.1007/s00262-012-1322-5. Epub 2012 Aug 4.

36.

A multiagent filovirus DNA vaccine delivered by intramuscular electroporation completely protects mice from ebola and Marburg virus challenge.

Grant-Klein RJ, Van Deusen NM, Badger CV, Hannaman D, Dupuy LC, Schmaljohn CS.

Hum Vaccin Immunother. 2012 Nov 1;8(11):1703-6. doi: 10.4161/hv.21873. Epub 2012 Aug 24.

37.

In vivo electroporation improves therapeutic potency of a DNA vaccine targeting hepadnaviral proteins.

Khawaja G, Buronfosse T, Jamard C, Abdul F, Guerret S, Zoulim F, Luxembourg A, Hannaman D, Evans CF, Hartmann D, Cova L.

Virology. 2012 Nov 10;433(1):192-202. doi: 10.1016/j.virol.2012.07.014. Epub 2012 Aug 24.

38.

A DNA-based candidate HIV vaccine delivered via in vivo electroporation induces CD4 responses toward the α4β7-binding V2 loop of HIV gp120 in healthy volunteers.

Kopycinski J, Cheeseman H, Ashraf A, Gill D, Hayes P, Hannaman D, Gilmour J, Cox JH, Vasan S.

Clin Vaccine Immunol. 2012 Sep;19(9):1557-9. doi: 10.1128/CVI.00327-12. Epub 2012 Jul 25.

39.

Immunogenicity of DNA vaccines encoding simian immunodeficiency virus antigen targeted to dendritic cells in rhesus macaques.

Tenbusch M, Ignatius R, Nchinda G, Trumpfheller C, Salazar AM, Töpfer K, Sauermann U, Wagner R, Hannaman D, Tenner-Racz K, Racz P, Stahl-Hennig C, Uberla K.

PLoS One. 2012;7(6):e39038. doi: 10.1371/journal.pone.0039038. Epub 2012 Jun 12.

40.

Electroporation of a multivalent DNA vaccine cocktail elicits a protective immune response against anthrax and plague.

Albrecht MT, Livingston BD, Pesce JT, Bell MG, Hannaman D, Keane-Myers AM.

Vaccine. 2012 Jul 6;30(32):4872-83. doi: 10.1016/j.vaccine.2012.04.078. Epub 2012 May 23.

PMID:
22633906
41.

A DNA vaccination regime including protein boost and electroporation protects cattle against foot-and-mouth disease.

Fowler V, Robinson L, Bankowski B, Cox S, Parida S, Lawlor C, Gibson D, O'Brien F, Ellefsen B, Hannaman D, Takamatsu HH, Barnett PV.

Antiviral Res. 2012 Apr;94(1):25-34. doi: 10.1016/j.antiviral.2012.02.002. Epub 2012 Feb 11.

PMID:
22330893
42.

Delivery of a DNA vaccine for Alzheimer's disease by electroporation versus gene gun generates potent and similar immune responses.

Davtyan H, Ghochikyan A, Movsesyan N, Ellefsen B, Petrushina I, Cribbs DH, Hannaman D, Evans CF, Agadjanyan MG.

Neurodegener Dis. 2012;10(1-4):261-4. doi: 10.1159/000333359. Epub 2012 Feb 1.

43.

Enhanced magnitude and breadth of neutralizing humoral response to a DNA vaccine targeting the DHBV envelope protein delivered by in vivo electroporation.

Khawaja G, Buronfosse T, Jamard C, Guerret S, Zoulim F, Luxembourg A, Hannaman D, Evans C, Hartmann D, Cova L.

Virology. 2012 Mar 30;425(1):61-9. doi: 10.1016/j.virol.2012.01.001. Epub 2012 Jan 28.

44.

In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers.

Vasan S, Hurley A, Schlesinger SJ, Hannaman D, Gardiner DF, Dugin DP, Boente-Carrera M, Vittorino R, Caskey M, Andersen J, Huang Y, Cox JH, Tarragona-Fiol T, Gill DK, Cheeseman H, Clark L, Dally L, Smith C, Schmidt C, Park HH, Kopycinski JT, Gilmour J, Fast P, Bernard R, Ho DD.

PLoS One. 2011;6(5):e19252. doi: 10.1371/journal.pone.0019252. Epub 2011 May 16.

45.

A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates.

Dupuy LC, Richards MJ, Ellefsen B, Chau L, Luxembourg A, Hannaman D, Livingston BD, Schmaljohn CS.

Clin Vaccine Immunol. 2011 May;18(5):707-16. doi: 10.1128/CVI.00030-11. Epub 2011 Mar 30.

46.

Electroporation enhances immunogenicity of a DNA vaccine expressing woodchuck hepatitis virus surface antigen in woodchucks.

Liu KH, Ascenzi MA, Bellezza CA, Bezuidenhout AJ, Cote PJ, Gonzalez-Aseguinolaza G, Hannaman D, Luxembourg A, Evans CF, Tennant BC, Menne S.

J Virol. 2011 May;85(10):4853-62. doi: 10.1128/JVI.02437-10. Epub 2011 Mar 9.

47.

Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation.

Dolter KE, Evans CF, Ellefsen B, Song J, Boente-Carrera M, Vittorino R, Rosenberg TJ, Hannaman D, Vasan S.

Vaccine. 2011 Jan 17;29(4):795-803. doi: 10.1016/j.vaccine.2010.11.011. Epub 2010 Nov 19.

PMID:
21094270
48.

Electroporation enhances immune responses and protection induced by a bovine viral diarrhea virus DNA vaccine in newborn calves with maternal antibodies.

van Drunen Littel-van den Hurk S, Lawman Z, Wilson D, Luxembourg A, Ellefsen B, van den Hurk JV, Hannaman D.

Vaccine. 2010 Sep 7;28(39):6445-54. doi: 10.1016/j.vaccine.2010.07.045. Epub 2010 Jul 27.

PMID:
20670907
49.

Electroporation for DNA immunization: clinical application.

van Drunen Littel-van den Hurk S, Hannaman D.

Expert Rev Vaccines. 2010 May;9(5):503-17. doi: 10.1586/erv.10.42. Review.

PMID:
20450325
50.

Codon-optimization of the hemagglutinin gene from the novel swine origin H1N1 influenza virus has differential effects on CD4(+) T-cell responses and immune effector mechanisms following DNA electroporation in mice.

Tenbusch M, Grunwald T, Niezold T, Storcksdieck Genannt Bonsmann M, Hannaman D, Norley S, Uberla K.

Vaccine. 2010 Apr 26;28(19):3273-7. doi: 10.1016/j.vaccine.2010.02.090. Epub 2010 Mar 4.

PMID:
20206668

Supplemental Content

Loading ...
Support Center